News & Events
- Tout
- Prix
- Communauté
- Profil du Réseau
- Communiqué de presse
- Points saillants de la recherche
Points saillants de la recherche Helping our immune system bypass antibiotic resistance
GlycoNet scientists are searching for ways to weaken bacteria’s ability to develop resistance.
Communiqué de presse GlycoNet Investigators leverage Network project to receive $1.15M in funding for breast cancer research
Funding will enable Drs. Yves St-Pierre, David Chatenet, and Nicolas Doucet to develop a revolutionary immunotherapy against breast cancer.
Points saillants de la recherche New family of enzymes reveals the Achilles’ heel of fungal pathogens
GlycoNet scientists share findings that could lead to therapeutics to treat fungal infections.
Prix GlycoNet Investigator honoured with prestigious award from the Canadian Society of Microbiologists
Dr. Lori Burrows received the 2020 CSM Murray Award for career achievement.
Prix GlycoNet Scientific Director receives award from American Chemical Society
Dr. Todd Lowary is named a recipient of Arthur C. Cope Late Career Scholars Award.
Prix GlycoNet Investigator recognized with Killam Research Fellowship
McMaster University professor Dr. Eric Brown has been awarded a Killam Research Fellowship.
Communiqué de presse GlycoNet Welcomes $16.3 Million Renewed Commitment from the Networks of Centres of Excellence for Glycomics Research
Founded in 2015, GlycoNet has been working to develop a collaborative national network to accelerate carbohydrate-based healthcare treatments, vaccine, and technologies for Canadians.
Profil du Réseau GlycoNet Announces New Chair of the Board of Directors
Ms. Karimah Es Sabar is appointed as Chair of GlycoNet Board of Directors.
Communiqué de presse Announcement of renewed funding from NCE
The Networks of Centres of Excellence (NCE) announced today the renewed funding for five NCE networks.
Points saillants de la recherche Preventing hospital-acquired pneumonia
GlycoNet researchers identified a previously unrecognized family of enzymes that put us at risk for deadly diseases.
Communiqué de presse Glycovax Pharma develops a vaccine against COVID-19
The biopharmaceutical company founded by GlycoNet Investigator is working to develop a semi-synthetic vaccine in the preclinical phase
Communiqué de presse GlycoNet-affiliated startup company searches for antiviral compounds to treat COVID-19
48Hour Discovery aims to develop clinically useful compounds by December 2020.
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 78-492-6204
Fax: 780-492-4147
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.
French 
English